Phase: III

A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly.
A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for12 weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy.
A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMARD Therapy.
A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
A Randomised Double-Blind, Placebo-and-Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended –Release (ER) in Subjects with Moderate to Severe Chronic Low Back Pain.
A randomised, double-blind, placebo-controlled study of the efficacy and safety of a diclofenac sodium patch for the topical treatment of acute pain due to mild to moderate soft tissue injuries.
A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of The Efficacy and Safety of Transdermal Buprenorphine (Norspan® TDS) And Placebo in Participants with Post Herpetic Neuralgia.
Open-label study to evaluate the Long-Term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects with Non-malignant Pain.
A confirmatory, placebo-controlled, randomised, double-blind, single dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal Hydromorphone – naloxone ratio with an improved bowel function and a comparable analgesic efficacy compared to Hydromorphone alone.